Mark Schrand
Internal Medicine · Cincinnati, OHNPI 1427056811
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $971 and has fallen 76.2% since, to $231 in 2023.
Across 132 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$367
- Lilly USA, LLC$267
- Novo Nordisk$211
- Boehringer Ingelheim$168
- Pfizer$167
- AstraZeneca$159
- plus $707 from 19 others
What the payments were for
- Food & beverage$2,044100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $367 |
| Lilly USA, LLC | 22 | $267 |
| Novo Nordisk | 13 | $211 |
| Boehringer Ingelheim | 14 | $168 |
| Pfizer | 10 | $167 |
| AstraZeneca | 9 | $159 |
| Amarin Pharma, Inc. | 7 | $148 |
| Amgen | 7 | $128 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $64 |
| Johnson & Johnson | 4 | $54 |
| Bayer | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $27 |
| Dexcom, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Novartis | 1 | $20 |
| GSK | 1 | $19 |
| Gilead | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $11 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$2,044 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Lisa LarkinCincinnati$276K
- Vincent MartinCincinnati$261K
- Kay JohnsonCincinnati$184K
- Jason HatfieldCincinnati$72K
- Rajbir MinhasCincinnati$62K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.